Interview | Elliot Marseille, Global Initiative for Psychedelic Science Economics (GIPSE) Post published:November 14, 2022 Post category:Interview
MindMed to Participate in the Jefferies London Healthcare Conference Post published:November 11, 2022 Post category:Press Release
Psychedelic Bulletin #123: Colorado Psilocybin Therapy Prop Passes While Swathes of Oregon Opt-out; Sensorium Closes $30m Series A Post published:November 11, 2022 Post category:Psychedelic Bulletin
FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Post published:November 10, 2022 Post category:Press Release
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update Post published:November 10, 2022 Post category:Press Release
Reunion Neuroscience Schedules Fiscal Second Quarter 2023 Conference Call for Monday, November 14, 2022, at 8:30 A.M. ET Post published:November 7, 2022 Post category:Press Release
MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial Results and Provide Business Update Post published:November 5, 2022 Post category:Press Release
Opinions | The Facts on Colorado Proposition 122 Post published:November 5, 2022 Post category:Opinions
Psychedelic Bulletin #122: Lusaris Raises $60m to Develop 5-MeO-DMT; First Take-Home Psilocybin Trial in N. America; COMPASS Phase 2b Published in NEJM Post published:November 4, 2022 Post category:Psychedelic Bulletin
COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights Post published:November 4, 2022 Post category:Press Release